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Abstract
Kidney cancer is one of the deadliest malignancies due to frequent late diagnosis (33 % or renal cell carcinoma
are metastatic at diagnosis) and poor treatment options. There are two major subtypes of kidney cancer: renal cell
carcinoma (RCC) and renal pelvis carcinoma. The risk factors for RCC, accounting for more than 90 % of all kidney
cancers, are smoking, obesity, hypertension, misuse of pain medication, and some genetic diseases. The most
common molecular markers of kidney cancer include mutations and epigenetic inactivation of von Hippel-Lindau
(VHL) gene, genes of vascular endothelial growth factor (VEGF) pathway, and carbonic anhydrase IX (CIAX). The role
of epigenetic pathways, including DNA methylation and chromatin structure remodeling, was also demonstrated.
Immunologic properties of RCC enable this type of tumor to escape immune response effectively. An important
role in this process is played by tumor-associated macrophages that demonstrate mixed M1/M2 phenotype. In this
review, we discuss molecular and cellular aspects for RCC development and current state of knowledge allowing
personalized approaches for diagnostics and prognostic prediction of this disease. A set of macrophage markers is
suggested for the analysis of the association of macrophage phenotype and disease prognosis.
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Introduction
Kidney cancer is one of the most common and deadly
malignancies, with approximately 58,000 new cases and
13,000 deaths estimated to have occurred in the USA in
2010 (http://www.cancer.gov/cancertopics/types/kidney).
There are two main types of kidney cancer, which in-
cludes renal cell carcinoma (RCC) and renal pelvis
carcinoma. RCC is the most prevalent, accounting for
90 % of all kidney cancers with 33 % of these cases being
metastatic at diagnosis [1]. Risk factors for the develop-
ment of RCC include cigarette smoking, obesity, contin-
ued misuse of pain medications, acquired cystic kidney
disease, hypertension, and other genetic diseases [2, 3].
The major problems in treating RCC are late diagnosis
and poor response to available therapies.
RCC arises from the proximal renal tubular epithe-
lium and involves several different cell types, such as
clear cells, granular cells, and spindle cells. The prox-
imal renal tubule plays an important role in homeostasis,
regulating pH, salt concentration, glucose concentration,
and other substances by reabsorption into the blood or
excretion with the urine [4]. There are both genetic and
epigenetic alterations that are connected to RCC develop-
ment. Genetic disorders leading to RCC and their genes of
mutation can be seen in Table 1 [5]. The most prevalent
genetic cause of RCC is von Hippel-Lindau syndrome, a
disorder characterized by the development of vascular
tumors such as RCC, hemangioblastomas of the central
nervous system and pheochromocytoma [5, 6]. The von
Hippel-Lindau (VHL) gene on chromosome 3 (3p25–26)
has been identified as a tumor suppressor gene for this
syndrome [5]. The VHL gene is inactivated in 75 % of
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RCC cases [7]. Patients inherit one mutated allele and ac-
quire a mutation in the second allele of the affected or-
gans. Patients who have non-inherited Hippel-Lindau
syndrome have acquired a mutation in both alleles [5].
Molecular predictive and prognostic markers
The three main predictive and prognostic markers used
for RCC are VHL, vascular endothelial growth factor
(VEGF), and carbonic anhydrase IX (CAIX) [3, 8]. The
first of which, VHL, has been studied immensely as a
biomarker. In a study by Yao et al., it was shown that
the presence of VHL alterations is associated with better
outcomes for patients with stages I–III clear cell RCC
treated by nephrectomy [9]. Mutational analyses showed
that almost 100 % of related RCC patients have germ
line VHL alterations; 42–57 % of sporadic clear cell RCC
patients have somatic intragenic mutations, and in 5–19 %
of these tumors, aberrant hypermethylation of VHL has
also been found [9]. In another study by Choueiri et al., it
was found that patients with an alteration of the VHL
gene had a better response to anti-VEGF therapy as op-
posed to those with the wild-type gene [10].
VEGF is an important ligand involved in tumor angio-
genesis. When patients are effectively treated with VEGF-
targeted therapy, VEGF levels in the serum rise and
soluble VEGFR levels decrease. Therefore, these factors
are used as pharmacodynamic biomarkers [3]. In a study
by Rini et al., serum levels of these factors were measured
before and during treatment with VEGF-targeted therapy.
Patients with baseline levels of sVEGFR-3 were associ-
ated with a better prognosis, suggesting that these fac-
tors can be used as predictive markers in this type of
therapy [11]. Also, VEGF is a downstream marker of
HIF activation, making it a marker for VHL loss and
HIF deregulation [3].
CIAX is a protein induced by hypoxia, which is widely
found in RCC cells. This protein regulates the conver-
sion of carbon dioxide to carbonic acid, leading to pH
homeostasis in tumors during hypoxic conditions and
the accumulation of lactic acid [3]. CIAX has proved to
be an effective prognostic marker. In a study by San-
dlund et al., RCC patients were evaluated using tissue
microarray analysis and CAIX staining; patients with
more than 91 % of staining were associated with a better
prognosis than patients with low amounts of staining
[12, 13]. In another study by Li et al., serum levels of
CAIX were analyzed in patients; the level of CAIX was
statistically significant in relation to tumor stage, grade,
and size [14]. CAIX seems to be a sound marker for
prognostic purposes and for VHL/HIF deregulation.
There are further molecules that can be considered as
diagnostic and prognostic markers of kidney tumors.
These include HIF-1, Survivin, mTOR, CA9, PTEN, tyro-
sine kinases Akt and S6K, cytokines CCL5 and CXCL9,
caveolin-1, and some others. However, most of these pro-
teins are not specific for kidney pathology. For example,
Survivin, belonging to the family of apoptosis inhibitors,
can be considered as a ubiquitous marker of various can-
cers, since its expression cannot be detected in differenti-
ated cells of an adult organism and remains detectable
only in dividing cells. Quantitative analysis of its expres-
sion can also be used as a marker of poor prognosis [15].
Inactivation of PTEN phosphatase is as well typical for the
majority of tumor types—glioma, meningioma, melan-
oma, kidney tumor, hepatoma, cervical, mammary, and
prostate carcinoma, so that this marker cannot be consid-
ered specific too. Tyrosinkinases Akt and S6K are the
components of mTOR signaling pathway, regulating initi-
ation of protein translation in the cell, being responsible
for general cell metabolism. Literature data indicate that
analysis of рAkt and рS6K expression level in 20 patients
undergoing temsirolimus therapy can be used for predic-
tion of the efficacy of mTOR-targeting therapy [16].
Expression of caveolin-1, the component of membrane
caveole, is associated with bad prognosis of prostate, lung,
mammary gland, kidney, and esophagus tumors [17]. Pro-
tooncogene Bcl-2 is a candidate marker of a good progno-
sis in kidney cancer. In a study of 101 cases of kidney
tumors, a correlation with good prognosis of disease was
observed [18]. However, there are other studies, indicating
that there is no correlation between Bcl-2 and progno-
sis of the disease [19, 20]. More specific seems to be
the analysis of several markers. For instance, simultan-
eous increase of caveolin and the components of Akt/
mTOR-mediated signaling is a strong indicator of poor
prognosis of kidney cancer [21].
In addition to mutations, epigenetic gene regulation by
modifying DNA methylation is a further major mechan-
ism of cancer initiation and progression. There is clear
evidence that DNA hypermethylation of CpG islands
around the promoter regions silences tumor-suppressor
genes [22]. This process in turn closely couples with and
depends on histone deacetylation. In fact, abnormal his-
tone acetylation status has been demonstrated to initiate
undesirable phenotypic changes and cancer [23]. Hence,
histone deacetylases (HDAC) inhibitors are supposed to
be useful in cancer prevention, due to their ability to
Table 1 Hereditary renal cell syndromes with genes of
mutation
Syndrome Gene (chromosome)
von Hippel-Lindau VHL (3p25–26)
Hereditary papillary renal carcinoma C-Met proto-oncogene (7q31–34)
Hereditary leiomyomatosis RCC Fumarate hydratase (1q42–43)
Birt–Hogg–Dubé BHD1 (17p11)
Tuberous sclerosis TSC1 (9q34) or TSC2 (16p13)
Modified from [5]
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“reactivate” the expression of epigenetically silenced
genes, including those involved in differentiation, inva-
sion, and metastasis. During the last years, it was shown
that HDAC blockade significantly reduces RCC growth
and invasion in vitro and in vivo [24–26]. Nevertheless,
downregulating HDAC alone seems not to be sufficient
to induce long-lasting antitumor effects in clinical trials. It
is therefore necessary to further optimize the treat-
ment protocol, either by introducing an additional
compound [27, 28] or by identifying very specific tar-
get structures, manipulation of which strongly stops
progressive RCC dissemination.
Immune escape
It is believed that RCC is partially controlled by the im-
mune system because of the frequency of the disease in
immunosuppressed people, the amount of T cell infiltra-
tion to the tumor sites, and the ability of metastasis in
these individuals to regress spontaneously. Immune es-
cape in these tumors is caused by alterations in immune
cells, the tumor microenvironment, tumor loss of func-
tion, and tumor gain of function [29].
Around 40 % of RCC lesions have at least a partial loss
of MHC class I antigens, and 6 % show a complete loss
[30]. MHC class I antigen processing and presentation is
important for the recognition of tumor cells by CD8+
cytotoxic T lymphocytes (CTLs). Other molecules in-
volved in antigen presentation, such as the transporter-
associated with antigen processing (TAP) subunit 1, the
chaperone tapasin, and low-molecular weight protein 2
and 7 (LMP2 and LMP7) are also regularly downregu-
lated in RCC cells in comparison to surrounding normal
kidney epithelium [29]. It has also been found that the
RCC cells lack costimulatory molecules B7-1 and B7-2.
The lack of these cells causes deficient T cell activation
leading to T cell anergy and apoptosis.
RCC cells also escape immunity due to gains in func-
tion. HLA-G has been found to be upregulated in RCC.
This protein is involved in the immune system by inter-
acting with immunoglobulin-like killer inhibitory recep-
tors (KIRs) that are found on natural killer (NK) cells
and T lymphocytes [29]. When HLA-G is bound to
these receptors, it protects tumor cells from attack from
these cells. Effector cells can also be killed due to an in-
crease in apoptosis-inducing molecules. It was found
that when T cells were cocultivated with RCC cells,
more T-cells went into apoptosis than normal. This may
be because of an upregulation of tumor necrosis factor
(TNF)-related apoptosis inducing ligand (TRAIL), Fas
ligand (FasL), or CD70 [31].
Alterations in T cells and other immune cells also lead
to a decreased immune response in RCC patients. DCs
are poorly recruited to tumor tissues, and T cells are si-
lenced by the secretion of factors involved in the TCR
signaling transduction pathways. A downregulation of
the TCR zeta chain and p56 (Ick) has been found in the
tumor infiltrating lymphocytes of these patients, impair-
ing T cell activation [29].
The tumor microenvironment plays highly important
role in the RCC cells’ ability to escape immune responses.
The infiltration of lymphocytes, tumor-associated macro-
phages, and DCs to the tumor sites contributes to the
tumor. These cells are able to produce factors such as
TNF-α or IL-6 which promote tumor growth and IFN, IL-
4, or IL-13 that prevent proliferation [29, 31].
Tumor-associated macrophages in kidney cancer
The tumor is comprised of a heterogeneous micro-
environment of both malignant and normal stromal
cells [32] and contains a large amount of macrophages
called tumor-associated macrophages (TAMs). These
macrophages have the ability to reduce tumor growth
via non-specific cytotoxic mechanisms or specific cell
lysis [33, 34]. However, in most of the cases, TAMs are
modified in a way to aid in malignant cell progression,
invasiveness, and evasion of apoptosis [32]. Chemokines
such as monocyte chemotactic protein-1 (MCP-1), macro-
phage colony stimulating factor (M-CSF), and VEGF are
secreted by the tumor cells and attract macrophages to
the site of malignancy [35].
A variety of traits possessed by macrophages can then
aid in the progression of the tumor. One example is the
macrophage’s ability to aid in angiogenesis through the
release of angiogenic factors, such as cytokines and
matrix metalloproteinases. Tumors need angiogenesis
in order to grow and for metastasis. The process of
angiogenesis includes extracellular matrix degradation,
proliferation and migration of capillary endothelial cells
and differentiation of these cells into mature capillaries,
providing a route for nutrients and oxygen to enter the
tumor and for metastatic cells to exit the tumor into
circulation [35].
Tumor-associated macrophages have also been shown
to aid in tumor growth. These macrophages secrete vari-
ous factors such as EGF, TGF-β1, and basic FGF when
cocultured with tumor cells aiding in proliferation and
survival. Tumor-associated macrophages have also been
shown to be essential for tumor development in macro-
phage depletion studies [36].
It has been shown that macrophages exposed to apop-
totic tumor cells have reduced cytotoxicity and nitric
oxide production in response to interferon-gamma and
lipopolysaccharide. It has also been shown that macro-
phages exposed to apoptotic tumor cells increase the
growth of tumor cells by 40 % and tumor-associated
macrophages promote tumor angiogenesis, invasion,
intravasation, and metastasis in animal models [37].
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In kidney tumors, an association between the amount of
TAMs is well established. It was demonstrated that high
infiltration of tumor with CD163+ cells correlates with
poor clinical prognosis [38]. In the same study, the au-
thors demonstrate that direct coculture of macrophages
with RCC cells induces type 2 macrophage phenotype.
This is explained by the expression of membrane-type M-
CSF on the surface of RCC cells. At the same time, it was
shown that TAMs isolated out of RCC express not only
immunosuppressive IL-10 but also pro-inflammatory
chemokine CCL2 [39]. These macrophages also showed
enhanced eicosanoid production via activated 15-
lipolxygenase-2 pathway [39], what is typical for activation
of macrophages by TGFβ [40]. Though unexpected, an-
other specific property of TAMs in RCC is expression of
CCR8 associated with higher activity of Stat3-mediated
signaling, what is rather typical for inflammatory pheno-
type. These cells are considered to be capable of stimulat-
ing FoxP3 expression in T cells and have proangiogenic
activity [41]. There are more confirmations of pro-
inflammatory phenotype of TAMs in RCC. Petrella and
Vincenti reported that increased expression of IL1β, a
cytokine that may be produced by inflammatory macro-
phages, contribute to aggressive RCCs. This cytokine leads
to expression of matrix metalloproteinases (MMPs)−1, −3,
and −10 that contribute to tumor cell invasion [42].
There is also a connection between TAM density and
VEGF pathway. In the study by Toge et al., it was found
that in more progressive RCC, the VEGF level was higher
what correlated with higher numbers of TAM and higher
microvessel density. Also, VEGF level and TAM were sig-
nificantly higher in patients with recurrence. The authors
identified VEGF and TAM numbers as prognostic factors.
Moreover, TAM was the only independent prognostic fac-
tor by multivariate analysis [43]. These data are supported
by the study, demonstrating that VEGFR1 knockdown
leads to reduced macrophage infiltration in the tumor
[44].
It is clear that RCC TAMs show mixed phenotype what
makes the analysis of the balance between M1 and M2
type activation even more important. In the paper of Xu
et al., it was demonstrated that the number of TAMs has
only limited prognostic value while the analysis of CD11c/
CD206 balance provides a good possibility to determine
individual prognosis (low CD11c and high CD206 dens-
ities are associated with poor prognosis) [45].
Although most of the studies are performed on clear
cell RCC, the importance of TAMs was demonstrated
also for papillary renal cell carcinoma. Papillary RCC
can be subdivided in subtypes I and II based on histo-
logical criteria. Type II is associated with poor prognosis.
Although density of TAM CD68+ tam was similar in
both subtypes, the analysis of more specific markers re-
vealed that nearly all macrophages in type II tumors
express CD163, while in type I tumors, there were less
than 30 % CD163 positive. Higher number of CD163
cells was associated with higher density of capillaries as
defined by CD31 staining. These findings suggest the
functional impact of TAMs on the prognosis of papillary
RCC type II [46].
Personalized therapy
Since the loss of VHL expression (50–80 % cases of clear
cell renal cell carcinoma) is the most frequent molecular
event observed in kidney tumors, most of the targeted
drugs used for the treatment of this pathology are inhib-
itors of various components of signaling pathways re-
lated to VHL inactivation. However, it is important to
note that kidney tumors other than renal cell carcinoma,
i.e., papillary, chromophobe, collective duct, and other
types of renal cell carcinoma are not associated with
VHL inactivation. Therefore, search for new molecular
markers and signaling pathways which components can
become therapeutic targets is necessary for effective
treatment of RCC.
The currently available therapeutic agents for advanced
RCC include one monoclonal antibody (bevacizumab),
four TKIs targeting VEGF receptors (VEGFRs) (sorafenib,
sunitinib, pazopanib, and axitinib), two inhibitors of the
mammalian target of rapamycin-related complexes (tem-
sirolimus and everolimus), and one recombinant form
of an endogenous cytokine (interleukin-2). At present,
sunitinib and pazopanib are the most frequently used
first-line treatments for advanced RCC. However, 25 %
of patients receiving this treatment will not obtain any
benefit, demonstrating early progression of the disease.
Secondary, resistance is also an important problem, as
most patients who initially respond to these agents will
eventually progress [47].
To increase RCC therapy efficacy, targeted drugs are
combined with antiangiogenic ones. The latter include
drugs that block HIF1α-VEGF signaling at several levels,
for example, combination of drugs that block VEGF and
its receptors. Other type of combined drug includes
blocking of several signaling pathways simultaneously,
i.e., VEGF, PDGF, EGF signaling pathways and mTOR
pathway [48, 49].
Several germline studies have investigated the effect of
polymorphisms on the efficacy and toxicity of antiangio-
genic agents, mainly focusing on genes-encoding enzymes
involved in metabolism (CYP3A4, CYP3A5, and their
regulator NR1I3), transporters (ABCB1 and ABCG2), and
targets (VEGF, VEGFRs, and FLT3) of these drugs. The
first pharmacogenetic study of sunitinib supported the
impact of SNPs in NR1I3, ABCB1, and CYP3A5 on
progression-free survival [50], and a subsequent study
revealed an association between two VEGFR3 missense
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polymorphisms and poor outcome with sunitinib treat-
ment [51].
In a recent study of patients treated with pazopanib, Xu
et al. [52] found an association between progression-free
survival and SNPs in IL8 and HIF1A, and the association
between UGT1A1 polymorphisms and bilirubin elevation
in pazopanib-treated patients has recently been con-
firmed. Also, higher responses to antiangiogenic drugs
were reported in familial VHL-RCC (i.e., RCC with germ-
line VHL mutations) in some but not all studies [53–55].
Despite active development of therapeutic approaches
for RCC, it remains unclear how to select the optimal
therapy for a particular patient. In contrast to adenocar-
cinoma of the lung or colon where mutations in EGFR or
K-RAS are the markers clearly predicting the sensitivity of
tumor cells to EGFR inhibitors, the presence of VHL mu-
tations is not a clear indication for the use of VEGF/
VEGFR inhibitors or other antiangiogenic drugs. It is not
yet clear which VHL mutations lead to a complete loss of
function [56, 57].
Therefore to date, the clinical benefit an individual pa-
tient will derive from antiangiogenic therapy is highly
variable and largely unpredictable. Between 20 and 30 %
of patients with ccRCC derive no benefit from first-line
TKI treatment [47, 58]. In addition, these drugs are toxic
and expensive. There is thus great impetus to discover
biomarkers in RCC that can identify the subpopulation
of patients destined to gain maximal benefit from any
given drug.
Expert recommendation
Molecular markers, identified during last years provide
an excellent possibility for the development of a person-
alized and predictive approach for patient stratification
and development of treatment strategy. Classification of
these markers according to the recommendations of
EPMA provided in the section “Biomarker Discovery,
Validation, Standardisation and Practical Application in
Medical Practice” of the EPMA White Paper [59] will
improve the usage of these markers in clinical practice.
Data is available for genetic and epigenetic changes in
the tumor cells and immunologic properties of the tumor.
A complex study that will include investigation of all these
parameters, i.e., mutations, gene silencing by DNA methy-
lation, and properties of TAMs is needed. Special atten-
tion has to be given to tumor-associated macrophages.
Research papers indicate that simple measurement of
TAMs amount provides insufficient information; there-
fore, additional research is needed to collect more infor-
mation about favorable and detrimental macrophage
phenotypes. It is important not to limit the analysis to
simple discrimination between M1 and M2 macrophage
phenotype but to identify the effects of individual cyto-
kines in connection with personal properties of the
immune system. This can be achieved using the following
markers: CD68, for general macrophage identification;
CD163, mannose receptor; Stab1, for general M2 identifi-
cation; fibronectin, βIG-H3, MMP2, and MMP12, for IL-
4-induced effects; Id3, OLR1, HAMP, and YKL-39, for
TGFβ-induced effects; MCP1, MCP2, and TNF, for M1
identification.
The early diagnosis of RCC, however, remains to be
illusive. There are no reliable soluble markers that can be
detected in the blood or urine so far. Therefore, more com-
plex strategies have to be developed for early detection or
even prediction of RCC in accordance with the principles
of preventive and personalized medicine (PPPM) [60].
These may include analysis of mutation and methylation of
genes involved in RCC pathogenesis in circulating tumor
cells or in plasma DNA.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM and OK drafted the manuscript, JK edited the manuscript, and AG
conceived the study, coordinated drafting of the manuscript, and finalized
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by RSСF grant, project 14-15-00396 (AG) and by
Tomsk State University Competitiveness Improvement Program (JK).
Author details
1Institute of Transfusion Medicine and Immunology, Medical Faculty
Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
2Blokhin Cancer Research Center, Moscow, Russia. 3Red Cross Blood Service
Baden-Württemberg—Hessen, Mannheim, Germany. 4Laboratory for
Translational Cellular and Molecular Biomedicine, Tomsk State University,
Tomsk, Russia. 5Laboratory of the Tumour Stromal Cells Biology, Institute of
Carcinogenesis, Blokhin Cancer Research Center, Kashirskoye Shosse 24,
Moscow, Russia.
Received: 19 August 2015 Accepted: 18 September 2015
References
1. Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P, et
al. Phase II trial of interleukin-2 and interferon-alpha in patients with
renal cell carcinoma: clinical results and immunologic correlates of
response. J Immunother. 1997;20(4):301–11.
2. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking,
obesity, diuretic use, and coffee consumption as risk factors for renal cell
carcinoma. J Natl Cancer Inst. 1986;77(2):351–6.
3. Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol.
2009;21(3):266–71.
4. Braga VA. Teaching the renal tubular reabsorption of glucose using two
classic papers by Shannon et al. Adv Physiol Educ. 2011;35(2):114–6.
5. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet.
2009;373(9669):1119–32.
6. Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA. Negative
regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Proc Natl Acad Sci U S A. 1996;93(20):10595–9.
7. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ. A
molecule targeting VHL-deficient renal cell carcinoma that induces
autophagy. Cancer Cell. 2008;14(1):90–102.
8. Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M,
et al. Gene expression in kidney cancer is associated with cytogenetic
abnormalities, metastasis formation, and patient survival. Clin Cancer
Res. 2005;11(2 Pt 1):646–55.
Mickley et al. The EPMA Journal  (2015) 6:20 Page 5 of 7
9. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL
tumor suppressor gene alterations associated with good prognosis in
sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002;94(20):1569–75.
10. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-
Lindau gene status and response to vascular endothelial growth factor
targeted therapy for metastatic clear cell renal cell carcinoma. J Urol.
2008;180(3):860–5. discussion 5–6.
11. Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol.
2008;20(3):300–6.
12. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B,
Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in
human renal cell carcinoma. BJU Int. 2007;100(3):556–60.
13. Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin
Oncol. 2010;22(3):250–6.
14. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase
9 level is associated with postoperative recurrence of conventional renal
cell cancer. J Urol. 2008;180(2):510–3. discussion 3–4.
15. Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC, et al.
Survivin expression in renal cell carcinoma. Cancer Invest. 2008;26(9):929–35.
16. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential
histologic and molecular predictors of response to temsirolimus in patients
with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6):379–85.
17. Hehlgans S, Cordes N. Caveolin-1: an essential modulator of cancer cell
radio-and chemoresistance. Am J Cancer Res. 2011;1(4):521–30.
18. Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. Impact of frequent Bcl-2
expression on better prognosis in renal cell carcinoma patients. Br J Cancer.
2004;90(1):200–5.
19. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal
cell carcinoma. Urology. 1998;51(6):1057–61.
20. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, et al. Clinical
significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Urology. 2002;59(4):615–20.
21. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF. Combined
expression of caveolin-1 and an activated AKT/mTOR pathway predicts
reduced disease-free survival in clinically confined renal cell carcinoma.
Br J Cancer. 2008;98(5):931–40.
22. Arai E, Kanai Y. Genetic and epigenetic alterations during renal
carcinogenesis. Int J Clin Exp Pathol. 2010;4(1):58–73.
23. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer
therapy. Clin Exp Metastasis. 2008;25(2):183–9.
24. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al.
The histone deacetylase inhibitor valproic acid alters growth properties
of renal cell carcinoma in vitro and in vivo. J Cell Mol Med.
2009;13(8B):2376–85.
25. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. Valproic
acid blocks adhesion of renal cell carcinoma cells to endothelium and
extracellular matrix. J Cell Mol Med. 2009;13(8B):2342–52.
26. Juengel E, Bhasin M, Libermann T, Barth S, Michaelis M, Cinatl Jr J, et al.
Alterations of the gene expression profile in renal cell carcinoma after
treatment with the histone deacetylase-inhibitor valproic acid and
interferon-alpha. World J Urol. 2011;29(6):779–86.
27. Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, Jonas D, et al. Effects
of combined valproic acid and the epidermal growth factor/vascular
endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on
renal cell carcinoma cell lines in vitro. BJU Int. 2010;105(4):549–57.
28. Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L, et al.
Combining the receptor tyrosine kinase inhibitor AEE788 and the
mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits
adhesion and growth of renal cell carcinoma cells. BMC Cancer. 2009;9:161.
29. Seliger B, Schlaf G. Structure, expression and function of HLA-G in renal cell
carcinoma. Semin Cancer Biol. 2007;17(6):444–50.
30. Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, et al.
Analysis of the expression of HLA class I, proinflammatory cytokines and
chemokines in primary tumors from patients with localized and metastatic
renal cell carcinoma. Tissue Antigens. 2006;68(4):303–10.
31. Seliger B, Dressler SP, Lichtenfels R, Kellner R. Candidate biomarkers in renal
cell carcinoma. Proteomics. 2007;7(24):4601–12.
32. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S,
Beschin A, Raes G, et al. Classical and alternative activation of mononuclear
phagocytes: picking the best of both worlds for tumor promotion.
Immunobiology. 2006;211(6–8):487–501.
33. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat
shock protein-peptide complexes, reconstituted in vitro, elicit peptide-
specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med.
1997;186(8):1315–22.
34. Grabbe S, Bruvers S, Beissert S, Granstein RD. Interferon-gamma inhibits
tumor antigen presentation by epidermal antigen-presenting cells.
J Leukoc Biol. 1994;55(6):695–701.
35. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages
in tumour progression: implications for new anticancer therapies. J Pathol.
2002;196(3):254–65.
36. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK,
et al. Eosinophils sustain adipose alternatively activated macrophages
associated with glucose homeostasis. Science. 2011;332(6026):243–7.
37. Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of
apoptotic versus necrotic tumor cells on macrophage antitumor activities.
J Immunol. 1999;163(4):1730–2.
38. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, et al.
Macrophage infiltration and its prognostic relevance in clear cell renal cell
carcinoma. Cancer Sci. 2011;102(7):1424–31.
39. Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, et al.
Tumor-associated macrophages mediate immunosuppression in the renal
cancer microenvironment by activating the 15-lipoxygenase-2 pathway.
Cancer Res. 2011;71(20):6400–9.
40. Gratchev A, Kzhyshkowska J, Kannookadan S, Ochsenreiter M, Popova A,
Yu X, et al. Activation of a TGF-beta-specific multistep gene expression
program in mature macrophages requires glucocorticoid-mediated surface
expression of TGF-beta receptor II. J Immunol. 2008;180(10):6553–65.
41. Eruslanov E, Stoffs T, Kim WJ, Daurkin I, Gilbert SM, Su LM, et al. Expansion
of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial
and renal carcinomas. Clin Cancer Res. 2013;19(7):1670–80.
42. Petrella BL, Vincenti MP. Interleukin-1beta mediates metalloproteinase-
dependent renal cell carcinoma tumor cell invasion through the activation
of CCAAT enhancer binding protein beta. Cancer Med. 2012;1(1):17–27.
43. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal
cell carcinoma: the role of tumor-associated macrophages. Int J Urol.
2009;16(10):801–7.
44. Li C, Liu B, Dai Z, Tao Y. Knockdown of VEGF receptor-1 (VEGFR-1) impairs
macrophage infiltration, angiogenesis and growth of clear cell renal cell
carcinoma (CRCC). Cancer Biol Ther. 2011;12(10):872–80.
45. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, et al. Prognostic value of
diametrically polarized tumor-associated macrophages in renal cell
carcinoma. Ann Surg Oncol. 2014;21(9):3142–50.
46. Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Strobel P, Radzun HJ.
Tumor-associated macrophages are involved in tumor progression in
papillary renal cell carcinoma. Virchows Arch. 2014;464(2):191–6.
47. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et
al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl
J Med. 2007;356(2):115–24.
48. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell
carcinoma. Cancer. 2009;115(10 Suppl):2368–75.
49. Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, et al. Sequential
targeted therapy after pazopanib therapy in patients with metastatic renal
cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014;12(4):262–9.
50. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van
Erp NP, et al. Genetic polymorphisms associated with a prolonged
progression-free survival in patients with metastatic renal cell cancer treated
with sunitinib. Clin Cancer Res. 2011;17(3):620–9.
51. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG,
Climent MA, et al. Single nucleotide polymorphism associations with
response and toxic effects in patients with advanced renal-cell carcinoma
treated with first-line sunitinib: a multicentre, observational, prospective
study. Lancet Oncol. 2011;12(12):1143–50.
52. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, et al.
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic
markers in angiogenesis-related and exposure-related genes. J Clin Oncol.
2011;29(18):2557–64.
53. Kim HC, Lee JS, Kim SH, So HS, Woo CY, Lee JL. Sunitinib treatment for
metastatic renal cell carcinoma in patients with von Hippel-Lindau disease.
Cancer Res Treat. 2013;45(4):349–53.
54. Tsimafeyeu I, Demidov L. Treatment options for renal cell carcinoma in
patients with von Hippel-Lindau disease. J Cancer Res Ther. 2010;6(4):575–7.
Mickley et al. The EPMA Journal  (2015) 6:20 Page 6 of 7
55. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, et
al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Ann Oncol. 2011;22(12):2661–6.
56. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al.
Comprehensive mutational analysis of the VHL gene in sporadic renal
cell carcinoma: relationship to clinicopathological parameters. Genes
Chromosomes Cancer. 2002;34(1):58–68.
57. Kawakami T, Okamoto K, Ogawa O, Okada Y. Multipoint methylation and
expression analysis of tumor suppressor genes in human renal cancer cells.
Urology. 2003;61(1):226–30.
58. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.
Pazopanib in locally advanced or metastatic renal cell carcinoma: results
of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.
59. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations
in predictive, preventive and personalised medicine 2012: white paper of
the European Association for Predictive, Preventive and Personalised
Medicine. EPMA J. 2012;3(1):14.
60. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA
position paper in cancer: current overview and future perspectives.
EPMA J. 2015;6(1):9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mickley et al. The EPMA Journal  (2015) 6:20 Page 7 of 7
